ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

In Brief: fraud By Trainee Leads Collins To Retract Five Paper; Weinstein Retires At Columbia

November 1, 1996

Tobacco Linked To 63 Percent Of Cancer Deaths In Black Men

July 29, 2005

Estrogen-Only HRT Little Risk In Endometrial Cancer, GOG Study Indicates

March 26, 2004

In Brief: Treatment Reorganization Plan Due In November, Rauscher Says; Panel To Review Clinical Activities

June 27, 1975

Smoking, Drinking Factors Affect Adherence to Preventive Regimen

September 30, 2011

Shubik Subcommittee Criticizes New Study Section, Asks NCI To Hire More Epidemiologists

December 5, 1975